Supernus and Indivior Agree to $2.2B Merger of Equals in CNS Medicine
Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered a definitive all-stock merger agreement to form a diversified central-nervous-system company with approximately $2.2 billion in combined annual revenue. Indivior shareholders are expected to own 56.5% of…
